Diaceutics finds 156K cancer patients could miss out on life-saving drugs every year in US and Europe

May 18th, 2017



Diaceutics, the medtech company enabling better patient testing globally, today announces research results showing that more than 156,000 cancer patients in the US and Europe could be missing out on targeted life-saving drugs every year due to suboptimal diagnostic testing – therefore potentially affecting their chances of survival. Diaceutics has also found that substandard testing practices are causing pharmaceutical companies in the US and Europe to miss out on up to $16.6 billion in potential revenues annually.

Latest Blogs

View all